Related Experiment Videos

Mycobacterium tuberculosis in children with human immunodeficiency virus type 1 infection

Y F Khouri1, M T Mastrucci, C Hutto

  • 1Department of Pediatrics D4-4, University of Miami School of Medicine, FL 33101.

Insights

Children with vertically acquired human immunodeficiency virus type 1 infection and tuberculosis face a higher risk of extrapulmonary disease. Multidrug-resistant tuberculosis is a growing concern in this vulnerable population.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • Vertically acquired human immunodeficiency virus type 1 (HIV-1) infection poses significant health challenges in children.
  • Tuberculosis (TB) is a major opportunistic infection in individuals with HIV-1.
  • Understanding the natural history of TB in vertically HIV-1-infected children is crucial for timely diagnosis and management.

Purpose of the Study:

  • To evaluate the natural history of Mycobacterium tuberculosis infection in children with vertically acquired HIV-1 infection.
  • To identify common presenting symptoms and disease patterns.
  • To assess the impact of drug resistance on treatment outcomes and survival.

Main Methods:

  • Retrospective study design.
  • Analysis of medical records of nine children with vertically acquired HIV-1 and TB.
  • Review of clinical presentation, diagnostic findings, treatment, and outcomes.

Main Results:

  • Common symptoms included prolonged fever, cough, and anorexia.
  • Five patients had pulmonary TB, three had pulmonary and extrapulmonary TB, and one had extrapulmonary TB.
  • Isolates cultured after January 1989 showed resistance to multiple antituberculosis drugs, unlike earlier isolates.
  • Median survival time after TB diagnosis was 20 months.

Conclusions:

  • Children with vertically acquired HIV-1 and TB have an increased risk of extrapulmonary disease.
  • A high index of suspicion for TB is warranted in HIV-1-infected children with persistent fever and respiratory symptoms.
  • Empirical therapy with a broader drug panel may be necessary in areas with multidrug-resistant TB.

Related Concept Videos